fluorouracil has been researched along with Anticipatory Vomiting in 26 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 7.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 7.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 6.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "Recently, high-dose FEC (fluorouracil, epirubicin, and cyclophosphamide) has been increasingly used in adjuvant chemotherapy for breast cancer in Japan." | 5.11 | [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients]. ( Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y, 2005) |
| "Hepatic arterial infusion chemotherapy with levofolinate (l-leucovorin) and fluorouracil regimen was performed using an implanted port system on unresectable hepatic metastasis patients with colorectal cancer." | 3.73 | [Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer]. ( Fujino, H; Hata, K; Kitamura, N; Kobuchi, T; Maruhashi, K; Nakamura, T; Shimomatsuya, T; Shiraishi, S, 2006) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 3.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 3.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 2.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| "The subjects were patients with squamous cell carcinoma of the oral cavity who had not received any therapy, comprising 7 patients with carcinoma of the tongue, 2 with buccal carcinoma, 2 with maxillary gingival carcinoma, and 1 with carcinoma of the oral floor." | 2.70 | [Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer]. ( Ando, T; Fukada, K; Hoshino, M; Kuwazawa, T; Maruoka, Y; Nishihara, N; Ogiuchi, H; Ogiuchi, Y; Okamoto, T, 2002) |
| "To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting." | 2.69 | The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000) |
| " Each chemotherapeutic drug has the potential to induce various adverse events in the patients receiving chemotherapy." | 2.41 | [Prevention and treatment for adverse events induced by chemotherapy]. ( Tsukuda, M, 2002) |
| "AN, as well as anticipatory vomiting (AV), distress, and worry/anxiety, were measured prior to the fourth, sixth, and last cycle of chemotherapy." | 1.34 | Anticipatory nausea: the role of individual differences related to sensory perception and autonomic reactivity. ( Jensen, AB; Johansson, A; Mehlsen, M; Paulsen, K; von der Maase, H; Zachariae, R, 2007) |
| "The number of elderly patients with colorectal cancer is increasing in Japan." | 1.34 | [Chemotherapy for elderly patients with colorectal cancer]. ( Kuboki, Y; Mizunuma, N, 2007) |
| " In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen." | 1.34 | [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| "The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy." | 1.33 | [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. ( Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005) |
| " In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events." | 1.33 | [Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006) |
| "Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy." | 1.32 | Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. ( Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 21 (80.77) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsukuda, M | 2 |
| Hosokawa, A | 1 |
| Yamada, Y | 2 |
| Shimada, Y | 1 |
| Muro, K | 1 |
| Matsumura, Y | 1 |
| Fujita, S | 1 |
| Akasu, T | 1 |
| Moriya, Y | 1 |
| Shirao, K | 1 |
| Tai, CJ | 1 |
| Liu, JH | 1 |
| Chen, WS | 1 |
| Lin, JK | 1 |
| Wang, WS | 1 |
| Yen, CC | 1 |
| Chiou, TJ | 1 |
| Chen, PM | 1 |
| Ishida, K | 1 |
| Ando, N | 1 |
| Yamamoto, S | 1 |
| Ide, H | 1 |
| Shinoda, M | 1 |
| Nakamura, Y | 1 |
| Momokawa, K | 1 |
| Sasaki, T | 1 |
| Sakayauchi, T | 1 |
| Watanabe, T | 1 |
| Mikami, T | 1 |
| Matsumoto, T | 1 |
| Ito, T | 1 |
| Hata, Y | 1 |
| Matsuoka, S | 1 |
| Nakajima, N | 1 |
| Yokoyama, R | 1 |
| Honda, S | 1 |
| Sano, F | 1 |
| Akasaka, Y | 1 |
| Ohmori, K | 1 |
| Kim, SJ | 1 |
| Taguchi, T | 3 |
| Miyoshi, Y | 1 |
| Tanji, Y | 1 |
| Tamaki, Y | 1 |
| Noguchi, S | 1 |
| Tanigaki, Y | 1 |
| Mikami, Y | 1 |
| Matsuda, H | 1 |
| Horiuchi, C | 1 |
| Yoshida, T | 1 |
| Ishitoya, J | 1 |
| Katori, H | 1 |
| Ikeda, Y | 1 |
| Ohta, K | 1 |
| Dohden, K | 1 |
| Morishita, M | 1 |
| Hayashi, H | 1 |
| Hattori, M | 1 |
| Hosokawa, O | 1 |
| Morita, M | 1 |
| Kaizaki, Y | 1 |
| Kiya, T | 1 |
| Shimomatsuya, T | 1 |
| Kobuchi, T | 1 |
| Kitamura, N | 1 |
| Hata, K | 1 |
| Nakamura, T | 1 |
| Shiraishi, S | 1 |
| Fujino, H | 1 |
| Maruhashi, K | 1 |
| Inaji, H | 1 |
| Sakai, K | 1 |
| Oka, T | 1 |
| Ozawa, K | 1 |
| Saito, Y | 1 |
| Senoo, T | 1 |
| Terasawa, T | 1 |
| Nakao, K | 1 |
| Mori, T | 1 |
| Koyama, H | 1 |
| Oshima, A | 1 |
| Zachariae, R | 1 |
| Paulsen, K | 1 |
| Mehlsen, M | 1 |
| Jensen, AB | 1 |
| Johansson, A | 1 |
| von der Maase, H | 1 |
| Kuboki, Y | 1 |
| Mizunuma, N | 1 |
| Maruoka, Y | 2 |
| Ando, T | 2 |
| Ogiuchi, Y | 2 |
| Ogiuchi, H | 2 |
| Yamamitsu, S | 1 |
| Kimura, H | 1 |
| Inui, N | 1 |
| Hiyama, S | 1 |
| Hirata, K | 1 |
| Kimura, Y | 1 |
| Shirasaka, T | 3 |
| Fredrikson, M | 1 |
| Fürst, CJ | 1 |
| Lekander, M | 1 |
| Rotstein, S | 1 |
| Blomgren, H | 1 |
| Asato, Y | 1 |
| Yoshimi, F | 1 |
| Ono, H | 1 |
| Amemiya, R | 1 |
| Koizumi, S | 1 |
| Hasegawa, H | 1 |
| Miya, T | 1 |
| Goya, T | 1 |
| Fujii, M | 1 |
| Kanke, M | 1 |
| Tomita, T | 1 |
| Miyashita, M | 1 |
| Onda, M | 1 |
| Ikeda, K | 1 |
| Bando, K | 1 |
| Hagiwara, N | 1 |
| Tsuchiya, Y | 1 |
| Yoshiyuki, T | 1 |
| Kiyama, T | 1 |
| Saito, T | 1 |
| Sasajima, K | 1 |
| Yamashita, K | 1 |
| Minamide, J | 1 |
| Aoyama, N | 1 |
| Koizumi, H | 1 |
| Yoneyama, K | 1 |
| Hoshino, S | 1 |
| Kamiya, J | 1 |
| Tamai, S | 1 |
| Kameda, Y | 1 |
| Sasaki, K | 1 |
| Yanagida, T | 1 |
| Ohya, M | 1 |
| Ishikawa, H | 1 |
| Tsuji, A | 1 |
| Morita, S | 1 |
| Horimi, T | 1 |
| Takasaki, M | 1 |
| Takahashi, I | 1 |
| Kohno, N | 1 |
| Kitahara, S | 1 |
| Tamura, E | 1 |
| Tanabe, T | 1 |
| Nakanoboh, M | 1 |
| Kawada, M | 1 |
| Yang, TS | 1 |
| Hsu, KC | 1 |
| Wang, HM | 1 |
| Lin, YC | 1 |
| Hoshino, M | 1 |
| Nishihara, N | 1 |
| Okamoto, T | 1 |
| Fukada, K | 1 |
| Kuwazawa, T | 1 |
| Ishida, T | 1 |
| Kusaba, T | 1 |
| Hayakawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Anticipatory Vomiting
| Article | Year |
|---|---|
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neop | 2002 |
12 trials available for fluorouracil and Anticipatory Vomiting
| Article | Year |
|---|---|
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2005 |
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, | 2005 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
[Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 1999 |
[Low-dose CDDP and 5-FU for head and neck cancer patients].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
Postoperative complications in patients of esophageal cancer after neoadjuvant chemotherapy.
Topics: Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Esophage | 1999 |
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
Phase II study of a weekly 8-hour 5-fluorouracil and leucovorin infusion for patients with advanced colorectal cancer: dose adjusted according to its toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 2001 |
[Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administ | 2002 |
13 other studies available for fluorouracil and Anticipatory Vomiting
| Article | Year |
|---|---|
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Adminis | 2003 |
[Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dexamethasone; Drug Administration S | 2005 |
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breas | 2006 |
[Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarr | 2006 |
Anticipatory nausea: the role of individual differences related to sensory perception and autonomic reactivity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arousal; Autonomic Nervous System; B | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2007 |
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2007 |
Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Chemotherapy | 1993 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |